Comparison 5. Methotrexate versus other DMARDs – major outcomes ≤ 6 months.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Disease response (ACR50)	1		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
1.1 Leflunomide (ACR50)	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2 Function (HAQ)	1		Mean Difference (IV, Random, 95% CI)	Totals not selected
2.1 Leflunomide	1		Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
3 Serious adverse events	3		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
3.1 Leflunomide	2		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Ciclosporin A	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4 Withdrawals due to adverse events	3		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected
4.1 Leflunomide	2		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 Ciclosporin A	1		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]